**Discussion Draft on Drug Compounding**

*Summary of the Bipartisan Senate Discussion Draft*

This discussion draft establishes a clear boundary between traditional compounders and compounding manufacturers, which make sterile products without or in advance of a prescription and sell those products across state lines. It clarifies a national, uniform set of rules for compounding manufacturers while preserving the states’ primary role in traditional pharmacy regulation. The draft creates a similar structure for oversight of compounded animal drugs, and clarifies the law on compounding from bulk chemicals for animals.

**Section 2: Regulation of Drug Compounding**

Clarification of New Drug Status

This section clarifies that compounded drugs are new drugs, and therefore the Federal Food, Drug, and Cosmetic Act (FFDCA) applies.

Section 503A: Drug Compounding

This section replaces section 503A in the current FFDCA. It defines compounding, compounding manufacturers, and traditional compounders, and the requirements on those entities; provides for exemptions from specified sections of the FFDCA for entities that comply with this section; creates a process for the Secretary to prohibit compounding of certain drug products; refines rules around the bulk chemicals that can be used in compounding; and establishes a fee structure to cover oversight of compounding manufacturers.

*Definitions*

The definitions of compounding and traditional compounder are drawn from current FFDCA section 503A. A compounding manufacturer is defined as an entity that compounds a sterile drug prior to or without receiving a prescription and introduces such drug into interstate commerce, with the exception that interstate shipment within a hospital system will not cause a hospital pharmacy to be considered a compounding manufacturer. Any entity that pools sterile products, or that repackages sterile, single-use, preservative-free vials would also be considered a compounding manufacturer. In order to maintain clear accountability, compounding manufacturers cannot be licensed as pharmacies.

*Exemptions from Requirements of FFDCA*

Drugs compounded by traditional compounders that meet the requirements set forth in the revised FFDCA section 503A are exempt from the FFDCA requirements regarding Good Manufacturing Practices (Sec. 501(a)(2)(B)), adequate directions for use (Sec. 502(f)(1)), and the new drug provisions (Sec. 505 for human drugs and Sec. 512 for animal drugs). Drugs compounded by compounding manufacturers that meet the requirements set forth in the revised FFDCA section 503A are exempt from the FFDCA requirements regarding adequate directions for use (Sec. 502(f)(1)) and the new drug provisions (Sec. 505 for human drugs and Sec. 512 for animal drugs), but are subject to applicable Good Manufacturing Practices.

*Drugs That May Not Be Compounded*

The Secretary may promulgate a regulation that designates drugs that may not be compounded due to the demonstrable difficulty of safely compounding these drugs, such as certain complex dosage forms and biologics. Until the regulation is finalized, the Secretary can designate products by notice following a 30-day comment period. This interim provision sunsets when the final regulation is effective or 5 years after the date of enactment, whichever occurs sooner.

Drugs removed from the market for safety and effectiveness reasons may not be compounded. However, the Secretary may allow a drug removed for human use to be compounded for animal use if appropriate.

Marketed FDA-approved drugs may not be compounded except in the case of a drug shortage. Variations of marketed-FDA approved drugs may be compounded only upon receipt of a prescription and if that variation provides a significant difference for that patient, as determined by the prescribing practitioner, between the compounded drug and the comparable marketed FDA approved drug.

Products subject to Risk Evaluation and Mitigation Strategies (REMS) with elements to assure safe use can only be compounded under these exceptions if the compounder shows the Secretary it utilizes controls that are comparable to those in the REMS.

*Bulk Ingredient Qualifications and Restriction on Wholesaling*

The bulk requirements in current section 503A are preserved, with one modification. Current law requires that any drug compounded from bulk must use bulk active pharmaceutical ingredient that 1) either complies with an applicable United States Pharmacopoeia (USP) or National Formulary (NF) monograph, is part of an FDA-approved drug, or appears on a list established by the Secretary; 2) is manufactured in a registered establishment; and 3) is accompanied by a valid certificate of analysis. The revised section 503A would permit the Secretary to identify a drug that only has an applicable USP or NF monograph as not suitable for compounding following the publication of the reasoning and consideration of comments submitted to a docket open for at least 30 days. Inactive ingredients also must comply with USP or NF.

If a drug is being compounded for a minor animal species, the same requirements on bulk chemicals apply. However, if a drug is compounded for a non-food major species or food-producing animal, compounding from bulk can only be performed if FDA has listed that bulk ingredient. The major species are cattle, horses, swine, chickens, turkeys, dogs, and cats. Minor animal species are all other species.

Compounded drugs may only be sold by the entity that compounded that product, and all must be labeled “not for resale”. It is a prohibited act to resell a product labeled “not for resale”.

*Compounding Manufacturer Requirements*

A compounding manufacturer must:

* Give a pharmacist licensed in the state where the compounding manufacturer is located direct oversight over the products compounded
* Report to the Secretary every 6 months the drugs sold in the previous 6 months
* Report serious adverse event experiences within 15 days, and do follow up investigation and reporting similar to current drug manufacturers
* Label products with a statement identifying it as compounded drug and other specified information about the drug. If a product is not labeled according to 503A, it is misbranded.

*Compounding Manufacturer Establishment and Reinspection Fees*

A compounding manufacturer would pay an annual establishment fee to defray the cost of compounding oversight (e.g. inspections). If a reinspection is required, that entire cost would be covered by the compounding manufacturer.

The fee is $15,000 per year with an inflation adjustment. Small businesses, defined as compounding manufacturers with 25 or less employees, would pay one-third of that fee. FDA would then adjust the fee for the larger facilities based on the number of small businesses. Fees can only be used for the inspection and regulation of compounding manufacturers.

The Secretary will provide an annual report to Congress on the fees collected from registration and reinspections, and the number of inspections completed in that fiscal year.

*Increasing State and FDA Communication*

FDA will encourage direct communication between the states regarding traditional compounders. However, if FDA receives a complaint report from a state regulatory agency about a specific traditional pharmacy or pharmacy product, the FDA must relay that information to the state pharmacy board where such facility is licensed within 15 days.

**Section 3: Other Requirements Relating To Compounding Manufacturers**

Application of Manufacturer Registration and Inspection Requirements to Compounding Manufacturers

This subsection clarifies that the pharmacy exemption in the Sec. 510 registration provisions does not apply for compounding manufacturers. Similarly, it clarifies the pharmacy exemption in Sec. 704 inspection authorities would not apply to compounding manufacturers.

**Section 4: Implementation**

Any regulations promulgated under this Act must be done through the rulemaking process (no interim final rules) and the final regulation must be published within 18 months of the proposed regulation.